The effects of glycine and lisinopril on anxiety, the social functioning of young males with hypertension and androgen deficiency
DOI: https://doi.org/10.29296/25877305-2021-11-17
Issue:
11
Year:
2021
Psychoemotional disorders worsen the course of somatic diseases. The presence of anxiety in males
with hypertension and androgen deficiency complicates the course of comorbidity and serves as a risk factor
for premature death, worse prognosis, and poorer social functioning in these patients. Complex
pathophysiology requires adequate antihypertensive and psychocorrective therapy. Glycine and lisinopril
therapy has been found to have a positive effect on the psychological state of patients with hypertension
and androgen deficiency and the social aspects of their lives.
Keywords:
терапия
кардиология
тревожность
социальное функционирование
артериальная гипертензия
андрогенодефицит
глицин
лизиноприл
References:
- El-Sakka A.I. Erectile dysfunction, depression, and ischemic heart disease: does the existence of one component of this triad necessitate inquiring the other two? J Sex Med. 2011; 8 (4): 937–40. DOI: 10.1111/j.1743-6109.2011.02231.x
- Habibulina M.M. Tserebral'naja gemodinamika pri arterial'noj gipertenzii i androgenodefitsite. Vrach. 2018; 29 (4): 26–32 [Khabibulina M. Cerebral hemodynamics in hypertension and androgen deficiency. Vrach. 2018; 29 (4): 26–32 (in Russ.)]. DOI: 10.29296/25877305-2018-04-04
- Fedorova N.N., Habibulina M.M. Sutochnyj profil' arterial'nogo davlenija u muzhchin s gipertonicheskoj bolezn'ju II stadii v zavisimosti ot urovnja testosterona. Mat-ly IV Vseross. konfe. «Protivorechija sovremennoj kardiologii: spornye i nereshennye voprosy». 2015; s. 40–2 [Fedorova N.N., Khabibulina M.M. Sutochnyi profil’ arterial’nogo davleniya u muzhchin s gipertonicheskoi bolezn’yu II stadii v zavisimosti ot urovnya testosterona. Mat-ly IV Vseross. konfe. «Protivorechiya sovremennoi kardiologii: spornye i nereshennye voprosy». 2015; r. 40–2 (in Russ.)].
- Fedorova N.N., Habibulina M.M. Remodelirovanie levyh kamer serdtsa u muzhchin s arterial'noj gipertenziej pri normal'nom i izmenennom gormonal'nom fone. Vrach. 2015; 12: 25–6 [Fedorova N., Khabibulina M. Left cardiac remodeling in male hypertensive patients having a normal or altered hormonal profile. Vrach. 2015; 12: 25–6 (in Russ.)].
- Fedorova N.N., Habibulina M.M. Strukturnye izmenenija miokarda levogo zheludochka u muzhchin s arterial'noj gipertoniej i androgenodefitsitom. Mezhdunarodnyj zhurnal eksperimental'nogo obrazovanija. 2015; 11: 690–2 [Fedorova N.N., Khabibulina M.M. Strukturnye izmeneniya miokarda levogo zheludochka u muzhchin s arterial’noi gipertoniei i androgenodefitsitom. International Journal of Experimental Education. 2015; 11: 690–2 (in Russ.)].
- Bardage C., Isacson D. hypertension and health – related quality of life – en epidemiological study in Sweden. J Clin Epidimiol. 2001; 54 (2): 172–81. DOI: 10.1016/s0895-4356(00)00293-6
- Klocer M. et al. Quality of life in patients with essential arterial hypertension. Part II – the effect of clinical factors. Przeql Lek. 2003; 60 (2): 101–6.
- Laumann E.O. et al. Sexual dysfunction in the United States: Prevalence and predictors. JAMA. 1999; 281 (6): 537–44. DOI: 10.1001/jama.281.6.537
- Fedorova N.N., Habibulina M.M. Osobennosti chuvstvitel'nosti organizma eksperimental'nyh zhivotnyh k vozdejstviju nekotoryh psihitropnyh preparatov v hronofarmakologicheskom aspekte. Vestnik Ural'skogo gosudarstvennogo meditsinskogo universiteta. 2015; 2–3: 281–3 [Fedorova N.N., Khabibulina M.M. Osobennosti chuvstvitel’nosti organizma eksperimental’nykh zhivotnykh k vozdeistviyu nekotorykh psikhitropnykh preparatov v khronofarmakologicheskom aspekte. Vestnik Ural’skogo gosudarstvennogo meditsinskogo universiteta. 2015; 2–3: 281–3 (in Russ.)].
- Petrova E.V., Vakina T.N., Burmistrova L.A. Seksual'nye disfunktsii pri trevozhno-depressivnyh rasstrojstvah. Lechaschij vrach. 2014; 5: 108–11 [Petrova E.V., Vakina T.N., Burmistrova L.A. Seksual’nye disfunktsii pri trevozhno-depressivnykh rasstroistvakh. Lechashchii vrach. 2014; 5: 108–11 (in Russ.)].
- Habibulina M.M. Sposob diagnostiki razvitija erektil'noj disfunktsii u molodyh muzhchin s arterial'noj gipertenziej v zavisimosti ot urovnja testosterona, pokazatelej lipidnogo spektra, EhoKG – pokazatelej. Patent na izobretenie RU2601405 C1, 10.11.2016. Zajavka №2015128439/15 ot 13.07.2015 [Khabibulina M.M. Sposob diagnostiki razvitiya erektil’noi disfunktsii u molodykh muzhchin s arterial’noi gipertenziei v zavisimosti ot urovnya testosterona, pokazatelei lipidnogo spektra, EkhoKG – pokazatelei. Patent na izobretenie RU2601405 C1, 10.11.2016. Zayavka №2015128439/15 ot 13.07.2015 (in Russ.)].
- Petrova E., Shutov A. Therapeutic correction testosterone deficiency in hypertensive men with erectile dysfunction and depression. J Sex Med. 2016; 13 (5, Suppl. 2): 146. DOI: 10.1016/j.jsxm.2016.03.172
- Fedorova N.N., Habibulina M.M. Otsenka pokazatelej gormonal'nogo balansa u muzhchin s arterial'noj gipertenziej pri razlichnyh tipah remodelirovanija levogo zheludochka. Kazanskij meditsinskij zhurnal. 2016; 97 (3): 323–7 [Fedorova N.N., Habibulina M.M. Evaluation of hormonal balance indicators in men with arterial hypertension in various types of left ventricular remodeling. Kazan medical journal. 2016; 97 (3): 323–7 (in Russ.)]. DOI: 10.17750/KMJ2016-323
- Vlachopoulos C., Ioakeimidis N., Terentes-Printzios D. et al. Plasma total testosterone and incident cardiovascular events in hypertensive patients. Am J Hypertens. 2013; 26: 373–81. DOI: 10.1093/ajh/hps056
- Rosmond R., Wallerius S., Wanger P. et al. A 5-year follow-up study of disease incidence in men with an abnormal hormone pattern. J Intern Med. 2003; 254 (4): 386–90. DOI: 10.1046/j.1365-2796.2003.01205.x
- Shores M.M., Matsumoto A.M., Sloan K.L. et al. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006; 166: 1660–5. DOI: 10.1001/archinte.166.15.1660
- Novo S., Iacona R., Bonomo V. et al. Erectile dysfunction is associated with low total serum testosterone levels and impaired flow-mediated vasodilation in intermediate risk men according to the Framingham risk score. Atherosclerosis. 2015; 238 (2): 415–9. DOI: 10.1016/j.atherosclerosis.2014.12.007
- Spitzer M., Basaria S., Travison T.G. et al. The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology. 2013; 1 (3): 475–82. DOI: 10.1111/j.2047-2927.2013.00075.x
- Lunenfeld B., Mskhalaya G., Zitzmann M. et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015; 18 (1): 5–15. DOI: 10.3109/13685538.2015.1004049
- Gathright E.C., Goldstein C.M., Josephson R.A. et al. Depression increases the risk of mortality in patients with heart failure: A meta-analysis. J Psychosom Res. 2017; 94: 82–9. DOI: 10.1016/j.jpsychores.2017.01.010
- Scalco A.Z., Scalco M.Z., Azul J.B.S. et al. Hypertension and depression. Clinics (Sao Paulo). 2005; 60 (3): 241–50. DOI: 10.1590/s1807-59322005000300010
- Nuralieva N.F., Napalkov D.A. Depressija i serdechno-sosudistye zabolevanija. Vestnik RAMN. 2014; 9–10: 21–6 [Nuralieva N.F., Napalkov D.A. Depression and cardiovascular diseases. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk = Annals of the Russian Academy of Medical Sciences. 2014; 9–10: 21–6 (in Russ.)]. DOI: 10.15690/vramn.v69i9-10.1127
- Fiedorowicz J.G. Depression and cardiovascular disease: an update on how course of illness may influence risk. Curr Psychiatry Rep. 2014; 16 (10): 492. DOI: 10.1007/s11920-014-0492-6
- Finnell J.E., Wood S.K. Neuroinflammation at the interface of depression and cardiovascular disease: Evidence from rodent models of social stress. Neurobiol Stress. 2016; 4: 1–14. DOI: 10.1016/j.ynstr.2016.04.001
- Atlantis E., Shi Z., Penninx B.J. et al. Chronic medical conditions mediate the association between depression and cardiovascular disease mortality. Soc Psychiatry Psychiatr Epidemiol. 2012; 47 (4): 615–25. DOI: 10.1007/s00127-011-0365-9
- Berntson J., Stewart K.R., Vrany E. et al. Depressive symptoms and self-reported adherence to medical recommendations to prevent cardiovascular disease: NHANES 2005-2010. Soc Sci Med. 2015; 138: 74–81. DOI: 10.1016/j.socscimed.2015.05.041
- Piepoli M.F., Hoes A.W., Agewall S. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016; 37 (29): 2315–81. DOI: 10.1093/eurheartj/ehw106
- Mamedov M.N. Problemy muzhskogo zdorov'ja v kardiologicheskoj praktike. 2-e izd. M.: Kardioprogress, 2014; 173 s. [Mamedov M.N. Problemy muzhskogo zdorov’ya v kardiologicheskoi praktike. 2-e izd. M.: Kardioprogress, 2014; 173 r. (in Russ.)].
- Chrysant S.G. Antihypertensive therapy causes erectile dysfunction. Curr Opin Cardiol. 2015; 30 (4): 383–90. DOI: 10.1097/HCO.0000000000000189
- Al Khaja K.A., Sequeira R.P., Alkhaja A.K. et al. Antihypertensive Drugs and Male Sexual Dysfunction: A Review of Adult Hypertension Guideline Recommendations. J Cardiovasc Pharmacol Ther. 2016; 21 (3): 233–44. DOI: 10.1177/1074248415598321
- DeLay K.J., Haney N., Hellstrom W. Modifying Risk Factors in the Management of Erectile Dysfunction: A Review. World J Mens Health. 2016; 34 (2): 89–100. DOI: 10.5534/wjmh.2016.34.2.89
- Habibulina M.M. Terapija pri remodelirovanii serdtsa u molodyh muzhchin s AG, androgenodefitsitom i dislipidemiej. Vrach. 2019; 30 (3): 44–8 [Khabibulina M. Therapy for cardiac remodeling in young men with hypertension, androgen deficiency, and dyslipidemia. Vrach. 2019; 30 (3): 44–9 (in Russ.)]. DOI: 10.29296/25877305-2019-03-09
- Habibulina M.M., Fedorova N.N. Zamestitel'naja gormonal'naja i kardiotropnaja terapija u molodyh muzhchin s AG, izbytochnoj massoj tela i androgenodefitsitom. Vrach. 2018; 29 (7): 78–83 [Khabibulina M., Fedorova N. Hormone replacement and cardiotropic therapy in young men with hypertension, overweight, and androgen deficiency. Vrach. 2018; 29 (7): 78–83 (in Russ.)]. DOI: 10.29296/25877305-2018-07-18
- Habibulina M.M., Fedorova N.N. Sposob optimizatsii lechenija muzhchin kardiotropnoj terapiej i zamestitel'noj gormonal'noj terapiej pri androgenodefitsite s arterial'noj gipertenziej. Patent na izobretenie RU2632449 C1, 04.10.2017. Zajavka №2016116414 ot 26.04.2016 [Khabibulina M.M., Fedorova N.N. Sposob optimizatsii lecheniya muzhchin kardiotropnoi terapiei i zamestitel’noi gormonal’noi terapiei pri androgenodefitsite s arterial’noi gipertenziei. Patent na izobretenie RU2632449 C1, 04.10.2017. Zayavka №2016116414 ot 26.04.2016 (in Russ.)].
- Habibulina M.M., Fedorova N.N. Kardiotropnaja i zamestitel'naja gormonal'naja terapija pri sochetanii AG s androgenodefitsitom. Vrach. 2016; 10: 65–9 [Khablbullna M., Fedorova N. Cardiotropic and hormone replacement therapy for arterial hypertension concurrent with androgen deficiency. Vrach. 2016; 10: 65–9 (in Russ.)].
- Casper R.F., Yen S.S. Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism. Clin Endocrinol (Oxford). 1985; 22 (3): 293–312. DOI: 10.1111/j.1365-2265.1985.tb03243.x